SELECTED
PUBLICATIONS

2023

Comparison of the Anti-Inflammatory Effects of Mouse Adipose- and Bone-Marrow-Derived Multilineage-Differentiating Stress-Enduring Cells in Acute-Phase Spinal Cord Injury

LEARN MORE

2023

Fetal Muse-based therapy prevents lethal radio-induced gastrointestinal syndrome by intestinal regeneration

LEARN MORE

2023

Role of glycosphingolipid SSEA-3 and FGF2 in the stemness and lineage commitment of multilineage differentiating stress enduring (MUSE) cells

LEARN MORE

2022

Endogenous reparative pluripotent Muse cells with a unique immune privilege system: Hint at a new strategy for controlling acute and chronic inflammation

LEARN MORE

2022

Naïve pluripotent-like characteristics of non-tumorigenic Muse cells isolated from human amniotic membrane

LEARN MORE

2022

Phagocytosing differentiated cell-fragments is a novel mechanism for controlling somatic stem cell differentiation within a short time frame

LEARN MORE

Clinical Trials & Clinical Data

2024

Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis

LEARN MORE

2024

Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)

LEARN MORE

2024

Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial

LEARN MORE

2024

Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatmen

LEARN MORE

2023

Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial

LEARN MORE

2023

Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke

LEARN MORE

NEWS

2024

Muse Cells: A New Stem Cell Treatment

LEARN MORE

MENU

SELECTED PUBLICATIONS

Comparison of the Anti-Inflammatory Effects of Mouse Adipose- and Bone-Marrow-Derived Multilineage-Differentiating Stress-Enduring Cells in Acute-Phase Spinal Cord Injury

Fetal Muse-based therapy prevents lethal radio-induced gastrointestinal syndrome by intestinal regeneration

Role of glycosphingolipid SSEA-3 and FGF2 in the stemness and lineage commitment of multilineage differentiating stress enduring (MUSE) cells

Endogenous reparative pluripotent Muse cells with a unique immune privilege system: Hint at a new strategy for controlling acute and chronic inflammation

Naïve pluripotent-like characteristics of non-tumorigenic Muse cells isolated from human amniotic membrane

Phagocytosing differentiated cell-fragments is a novel mechanism for controlling somatic stem cell differentiation within a short time frame

Clinical Trials & Clinical Data

Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis

Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)

Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial

Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatmen

Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial

Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke

NEWS

Muse Cells: A New Stem Cell Treatment

SELECTED
PUBLICATIONS